摘要
[目的]评价米托蒽醌、阿糖胞苷(MA)方案作诱导治疗成人急性非淋巴细胞白血病(ANLL)初治患者的疗效。[方法]对诊断明确者分为M1、M2型及M4、M5型,各型内部随机分为MA组和柔红霉素、阿糖胞苷(DA)组,1、2个疗程后,分别评价疗效。[结果]M1、M2型中,MA、DA组1个疗程后CR分别为70.0%、63.6%,2个疗程总CR分别为75.0%、68.2%,总有效率分别为85.0%、81.8%,两组间均无显著性差异。M4、M5型中,MA、DA组1个疗程CR分别为68.8%、33.3%,两者有显著差异,而2个疗程总CR分别为68.8%、46.7%,总有效率分别为81.3%、60.0%,两组间无显著性差异。MA组骨髓抑制作用强于传统DA组。[结论]MA方案可作为成人ANLL(M4、M5)首选诱导治疗方案。
To evaluate the effect of inductive therapy using MA regimen for previous untreated adult pa-tients with ANLL.The patients were separated into M 1 or M 2 type group and M 4 or M 5 type groups.Each type was randomly separated into two groups.One was treated with MA,the other with Daunorubin and cytosine arabinoside(DA).The effects of the two groups were compared after being treated with1cycle and2cycles.In M 4 or M 5 type group,the CR rate following1cycle treatment with MA regimen was68.8%.It was obviously higher than that with DA regimen,which was33.3%.The bone marrow depression was more serious in MA regimen than that in DA regimen.[Conclusion]MA regimen may be as the first choice for adult ANLL(M 4 ?M 5 ).
出处
《中国肿瘤》
CAS
2003年第4期232-233,共2页
China Cancer
